Bioporto A/S
CSE:BIOPOR
Bioporto A/S
Capital Expenditures
Bioporto A/S
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Capital Expenditures
-kr304m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
-15%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Capital Expenditures
-kr13.1m
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
-11%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Capital Expenditures
-€1.4m
|
CAGR 3-Years
61%
|
CAGR 5-Years
23%
|
CAGR 10-Years
-13%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Capital Expenditures
-kr1.3B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-27%
|
|
|
Saniona AB
STO:SANION
|
Capital Expenditures
-kr170k
|
CAGR 3-Years
60%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
You don't have any saved screeners yet